

## Supplemental Material

Major loss of solute carrier (SLC) – super family drug uptake transporters in human and rat cryopreserved hepatocytes.

Patrik Lundquist, Johan Lööf, Anna-Karin Sohlenius-Sternbeck, Eva Floby, Jenny Johansson, Johan Bylund, Janet Hoogstraate, Lovisa Afzelius, and Tommy B Andersson

Drug Metabolism and Disposition

## Supplemental Tables

**Supplemental Table 1.** Liver tissue and hepatocyte donor information

<b>Cryopreserved hepatocytes donors</b>						
Provider	Donor	Sex	Age	Cause of death <sup>a</sup>	Medical History	Medications
Celsis	OZL	M	53	CVA	Hypertension Diabetes	Anti-hypertensives
Celsis	REL	F	60	ICH	None reported	None reported
Celsis	SQJ	F	67	ICH	Hypertension	Anti-hypertensives
CellzDirect	4035	M	34	Head Injury	Colitis	None reported
CellzDirect	4037	F	64	CVA	Hypertension Multiple Sclerosis	None reported
CellzDirect	4152	F	50	Anoxia	None reported	None reported
<b>Liver tissue and fresh hepatocyte donors</b>						
	Donor	Sex	Age	Reason for hepatectomy <sup>b</sup>	Medical History	Medications
	A	F	23	FNH	None reported	None reported
	B	M	59	RC	None reported	Folinic acid <sup>c, d</sup> 5-Fluorouracil Oxaliplatin
	C	F	59	CC	None reported	Folinic acid <sup>c, d</sup> 5-Fluorouracil Oxaliplatin

<sup>a</sup>CVA, cerebrovascular accident/stroke ; ICH, intracerebral hemorrhage

<sup>b</sup>FNH, focal nodular hypoplasia; RC, rectal carcinoma; CC, carcinoid coli

<sup>c</sup>This combination of cytostatica is known as Folfox

<sup>d</sup>Livers from donors receiving oxaliplatin were devoid of obvious histological changes.

**Supplemental Table 2.** Primary antibodies: sources and species reactivity.

<b>Primary Antibody (catalogue #)</b>	<b>Observed species reactivity</b>
Rabbit polyclonal to MCT1 <sup>c</sup> , Human Protein Atlas <sup>a</sup>	Hu, Rat
Rabbit polyclonal to NTCP, University of Zürich <sup>b</sup>	Hu, Rat
Rabbit polyclonal to OAT2, Abcam (ab58683)	Hu, Rat
Rabbit polyclonal to OATP1B1, University of Zürich <sup>b</sup>	Hu
Rabbit polyclonal to OATP1B3, University of Zürich <sup>b</sup>	Hu
Rabbit polyclonal to OATP2B1, University of Zürich <sup>b</sup>	Hu, Rat
Rabbit polyclonal to OCT1, Abcam (ab55916)	Hu, Rat
Rabbit polyclonal to OCT3, Abcam (ab74152)	Hu, Rat
Rabbit polyclonal to PEPT1 <sup>d</sup> , Human Protein Atlas <sup>a</sup>	Hu, Rat
Goat polyclonal to GAPDH-HRP, Santa Cruz Biotechnology (sc20357)	Most mammals

<sup>a</sup>Antibodies from Human Protein Atlas ([www.proteinatlas.org](http://www.proteinatlas.org)) have been described previously (Nilsson et al., 2005, supplemental references).

<sup>b</sup>Antibodies from University of Zürich were kindly provided by Dr Bruno Stieger (Rippin et al., 2001, supplemental references).

<sup>c</sup>Monocarboxylate transporter 1, MCT1

<sup>d</sup>Peptide transporter 1, PEPT1

**Supplemental Table 3.** Test compound optimized settings for LC-MS/MS analysis.

<b>Compound</b>	<b>Transition m/z</b>	<b>Ion source mode</b>	<b>Cone voltage [V]</b>	<b>Collision energy [eV]</b>
7-Hydroxycoumarin	160.90 → 133.10	Negative	37.00	19.00
Diazepam	285.10 → 154.10	Positive	37.00	26.00
Diclofenac	293.80 → 250.10	Negative	19.00	12.00
Fexofenadine	502.00 → 171.12	Positive	30.00	40.00
Ipratropium	332.86 → 124.15	Positive	37.00	28.00
Midazolam	260.00 → 291.10	Positive	46.00	26.00
Phenacetin	180.10 → 110.10	Positive	37.00	19.00
Rosuvastatin	482.14 → 258.46	Positive	55.00	34.00
Taurocholate	514.09 → 123.85	Negative	64.00	50.00
Warfarin	308.90 → 163.01	Positive	18.00	16.00

### Supplemental References

Bergman E, Forsell P, Tevell A, Persson E, Hedeland M, Bindesson U, Knutson L, and Lennernäs H (2006) Biliary excretion of rosuvastatin and bile acids in humans during the absorption phase. *Eur J Pharm Sci* **29**: 205-214.

Ensing K, de Zeeuw RA, Nossent GD, Koëter GH, and Cornelissen PJ (1989) Pharmacokinetics of ipratropium bromide after single dose inhalation and oral and intravenous administration. *Eur J Clin Pharmacol* **36**: 189-194.

Kamath AV, Yao M, Zhang Y, and Chong S (2005) Effect of fruit juices on the oral bioavailability of fexofenadine in rats. *J Pharm Sci* **94**: 233-239.

Kitamura S, Maeda K, Wang Y, and Sugiyama Y (2008) Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. *Drug Metab Dispos* **36**: 2014-2023.

Nilsson P, Paavilainen L, Larsson K, Ödling J, Sundberg M, Andersson AC, Kampf C, Persson A, Al-Khalili Szigyarto C, Ottoson J, Björling E, Hober S, Wernérus H, Wester K, Ponten F, and Uhlen M (2005) Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. *Proteomics* **5**: 4327-4337.

Rippin SJ, Hagenbuch B, Meier PJ, and Stieger B (2001) Cholestatic expression pattern of sinusoidal and canalicular organic anion transport systems in primary cultured rat hepatocytes. *Hepatology* **33**: 776-782.

Swift B, Tian X, and Brouwer KL (2009) Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function. *Pharm Res* **26**: 1942-1951.

Urso R, Segre G, Bianchi E, Bruni G, Dal Pra P, and Fiaschi AI (1991) Plasma kinetics of atropine and ipratropium in rats after different routes of administration evaluated by a radioreceptor assay. *Eur J Drug Metab Pharmacokinet Spec No 3*: 111-115.

Varma M, Feng B, Obach R, Troutman M, Chupka J, Miller H, and El-Kattan A (2009) Physicochemical determinants of human renal clearance. *J Med Chem* **52**: 4844-4852.

Yang X, Gandhi Y, Duignan D, and Morris M (2009) Prediction of biliary excretion in rats and humans using molecular weight and quantitative structure-pharmacokinetic relationships. *AAPS J* **11**: 511-525.